Kostas Biliouris
Stock Analyst
(1.85)
# 2,733
Out of 4,648 analysts
47
Total ratings
37.5%
Success rate
-9.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $15.90 | +120.13% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $2.12 | +703.78% | 2 | Aug 15, 2024 | |
| IONS Ionis Pharmaceuticals | Downgrades: Market Perform | $67 → $60 | $38.55 | +55.64% | 1 | Aug 2, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $8.24 | +385.44% | 4 | Jul 18, 2024 | |
| LEGN Legend Biotech | Maintains: Outperform | $90 | $43.96 | +104.73% | 3 | Jul 3, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $234 | $270.94 | -13.63% | 4 | Jun 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $123.77 | +61.59% | 4 | Jun 24, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $120 | $60.45 | +98.51% | 3 | May 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $62 → $70 | $15.26 | +358.87% | 5 | May 10, 2024 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 | $24.76 | +130.26% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $25.33 | +46.07% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $17.74 | +277.68% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $66.20 | +51.06% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $4.05 | +369.14% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $210 → $120 | $8.31 | +1,344.03% | 2 | Mar 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $6.13 | +912.24% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $51.37 | +90.79% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $15.90
Upside: +120.13%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $2.12
Upside: +703.78%
Ionis Pharmaceuticals
Aug 2, 2024
Downgrades: Market Perform
Price Target: $67 → $60
Current: $38.55
Upside: +55.64%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.24
Upside: +385.44%
Legend Biotech
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $43.96
Upside: +104.73%
Alnylam Pharmaceuticals
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $270.94
Upside: -13.63%
Sarepta Therapeutics
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $123.77
Upside: +61.59%
Korro Bio
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $60.45
Upside: +98.51%
Intellia Therapeutics
May 10, 2024
Maintains: Outperform
Price Target: $62 → $70
Current: $15.26
Upside: +358.87%
Beam Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $24.76
Upside: +130.26%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $25.33
Upside: +46.07%
Jan 31, 2024
Initiates: Outperform
Price Target: $67
Current: $17.74
Upside: +277.68%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $66.20
Upside: +51.06%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $4.05
Upside: +369.14%
Mar 14, 2023
Downgrades: Market Perform
Price Target: $210 → $120
Current: $8.31
Upside: +1,344.03%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $6.13
Upside: +912.24%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $51.37
Upside: +90.79%